We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (IPNSAE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03957616
Recruitment Status : Unknown
Verified May 2019 by Hospices Civils de Lyon.
Recruitment status was:  Not yet recruiting
First Posted : May 21, 2019
Last Update Posted : May 21, 2019
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:
This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.

Condition or disease
Paraneoplastic Neurological Syndrome Autoimmune Encephalitis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018
Estimated Study Start Date : May 30, 2019
Estimated Primary Completion Date : May 30, 2019
Estimated Study Completion Date : July 31, 2019

Paraneoplastic neurological syndromes patients
Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.

Primary Outcome Measures :
  1. Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018. [ Time Frame: 3 years ]
    Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.

Secondary Outcome Measures :
  1. Location (city) of diagnosis [ Time Frame: 1 hour ]
    Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.

  2. French general population of each counties [ Time Frame: 3 years ]
    Person years for each region

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with a paraneoplastic neurological syndrome or autoimmune encephalitis in France and referred to the national center in Lyon between 2016 and 2018.

Inclusion Criteria:

- Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018

Exclusion Criteria:

  • Data on location of diagnosis missing
  • Patients diagnosed out of the mainland French territory
  • Patients for whom insufficient data was available

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03957616

Layout table for location contacts
Contact: Géraldine Picard 4 72 35 58 42 ext 33 geraldine.picard@chu-lyon.fr
Contact: Jérôme Honnorat 4 72 35 78 06 ext 33 jerome.honnorat@chu-lyon.fr

Layout table for location information
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Lyon, France, 69003
Sponsors and Collaborators
Hospices Civils de Lyon
Layout table for investigator information
Principal Investigator: Jérôme Honnorat center for paraneoplastic neurological syndromes and autoimmune encephalitis
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03957616    
Other Study ID Numbers: IPNSAE
First Posted: May 21, 2019    Key Record Dates
Last Update Posted: May 21, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hashimoto Disease
Pathologic Processes
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Thyroiditis, Autoimmune
Thyroid Diseases
Endocrine System Diseases